Current status of pretransplant intensive chemotherapy or hypomethylating agents for myelodysplastic syndrome

Christian Niederwieser; Nicolaus Kröger

doi:10.1016/j.beha.2021.101332

Current status of pretransplant intensive chemotherapy or hypomethylating agents for myelodysplastic syndrome

Standard

Current status of pretransplant intensive chemotherapy or hypomethylating agents for myelodysplastic syndrome. / Niederwieser, Christian ; Kröger, Nicolaus.

In: BEST PRACT RES CL HA, Vol. 34, No. 4, 101332, 12.2021.

Research output: SCORING: Contribution to journal › SCORING: Review article › Research

Harvard

Niederwieser, C & Kröger, N 2021, 'Current status of pretransplant intensive chemotherapy or hypomethylating agents for myelodysplastic syndrome', BEST PRACT RES CL HA, vol. 34, no. 4, 101332. https://doi.org/10.1016/j.beha.2021.101332

APA

Niederwieser, C., & Kröger, N. (2021). Current status of pretransplant intensive chemotherapy or hypomethylating agents for myelodysplastic syndrome. BEST PRACT RES CL HA, 34(4), [101332]. https://doi.org/10.1016/j.beha.2021.101332

Vancouver

Niederwieser C , Kröger N. Current status of pretransplant intensive chemotherapy or hypomethylating agents for myelodysplastic syndrome. BEST PRACT RES CL HA. 2021 Dec;34(4). 101332. https://doi.org/10.1016/j.beha.2021.101332

Bibtex

@article{4eaa17ac0651494cbb3a30e3972711e0,

title = "Current status of pretransplant intensive chemotherapy or hypomethylating agents for myelodysplastic syndrome",

abstract = "Myelodysplastic syndrome is a heterogeneous disease with survival probabilities ranging from a few months to several years. Allogeneic hematopoietic cell transplantation (HCT) remains the only curative treatment. Although access (up to 75 years) and outcome of HCT have improved steadily in recent years, high relapse rates and, to a lower extent, treatment related mortalities are a persisting problem. Reduction of tumor burden before HCT has been shown to decrease relapse incidence and often overall survival (OS) in hematological malignancies but the role of pretransplant therapy in MDS remains controversial. We reviewed the role of pretransplant therapy on outcome in MDS patients. No prospective randomized trial addressed this issue so far. Retrospective studies have shown that pretransplant therapy reduces the risk of relapse, but does not improve survival. In addition, registry studies from diagnosis with standard protocols are proposed in order to exclude patient selection. With the availability of new, more effective and low-toxicity therapies, it may be possible to achieve a significant improvement of OS in the future.",

keywords = "Hematopoietic Stem Cell Transplantation, Humans, Myelodysplastic Syndromes/drug therapy, Neoplasm Recurrence, Local, Retrospective Studies",

author = "Christian Niederwieser and Nicolaus Kr{\"o}ger",

note = "Copyright {\textcopyright} 2021. Published by Elsevier Ltd.",

year = "2021",

month = dec,

doi = "10.1016/j.beha.2021.101332",

language = "English",

volume = "34",

journal = "BEST PRACT RES CL HA",

issn = "1521-6926",

publisher = "Bailliere Tindall Ltd",

number = "4",

}

RIS

TY - JOUR

T1 - Current status of pretransplant intensive chemotherapy or hypomethylating agents for myelodysplastic syndrome

AU - Niederwieser, Christian

AU - Kröger, Nicolaus

PY - 2021/12

Y1 - 2021/12

N2 - Myelodysplastic syndrome is a heterogeneous disease with survival probabilities ranging from a few months to several years. Allogeneic hematopoietic cell transplantation (HCT) remains the only curative treatment. Although access (up to 75 years) and outcome of HCT have improved steadily in recent years, high relapse rates and, to a lower extent, treatment related mortalities are a persisting problem. Reduction of tumor burden before HCT has been shown to decrease relapse incidence and often overall survival (OS) in hematological malignancies but the role of pretransplant therapy in MDS remains controversial. We reviewed the role of pretransplant therapy on outcome in MDS patients. No prospective randomized trial addressed this issue so far. Retrospective studies have shown that pretransplant therapy reduces the risk of relapse, but does not improve survival. In addition, registry studies from diagnosis with standard protocols are proposed in order to exclude patient selection. With the availability of new, more effective and low-toxicity therapies, it may be possible to achieve a significant improvement of OS in the future.

AB - Myelodysplastic syndrome is a heterogeneous disease with survival probabilities ranging from a few months to several years. Allogeneic hematopoietic cell transplantation (HCT) remains the only curative treatment. Although access (up to 75 years) and outcome of HCT have improved steadily in recent years, high relapse rates and, to a lower extent, treatment related mortalities are a persisting problem. Reduction of tumor burden before HCT has been shown to decrease relapse incidence and often overall survival (OS) in hematological malignancies but the role of pretransplant therapy in MDS remains controversial. We reviewed the role of pretransplant therapy on outcome in MDS patients. No prospective randomized trial addressed this issue so far. Retrospective studies have shown that pretransplant therapy reduces the risk of relapse, but does not improve survival. In addition, registry studies from diagnosis with standard protocols are proposed in order to exclude patient selection. With the availability of new, more effective and low-toxicity therapies, it may be possible to achieve a significant improvement of OS in the future.

KW - Hematopoietic Stem Cell Transplantation

KW - Humans

KW - Myelodysplastic Syndromes/drug therapy

KW - Neoplasm Recurrence, Local

KW - Retrospective Studies

U2 - 10.1016/j.beha.2021.101332

DO - 10.1016/j.beha.2021.101332

M3 - SCORING: Review article

C2 - 34865704

VL - 34

JO - BEST PRACT RES CL HA

JF - BEST PRACT RES CL HA

SN - 1521-6926

IS - 4

M1 - 101332

ER -